Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21516

Shown on this page

Current sort

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 54
States / cities: Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more

Conditions: Multiple Sclerosis
Interventions: Frexalimab, Placebo, MRI contrast-enhancing agents; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 79
States / cities: Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more

Conditions: Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Barostim System, Usual care medical management; Device · Other
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Clearwater, Florida + 18 more

Conditions: Cystic Fibrosis-related Diabetes
Interventions: iLet Bionic Pancreas System (BP), Usual Care (UC); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 14 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more

Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions: Evolocumab, Routine Lipid Management; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more

Conditions: Lung Cancer, Smoking Behaviors, Diagnosis
Interventions: Educational Lung Cancer Screening (LCS) Video; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Caries,Dental
Interventions: LumiCare rinse, QLF Inspektor Pro Imaging; Device
Lead sponsor: Tufts University; Other
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 38 more

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 145
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more

Conditions: REM Sleep Behavior Disorder
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 13 more

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 17
States / cities: Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Intracranial Meningioma
Interventions: [177Lu]Lu-DOTATATE, Standard of Care treatments; Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Irvine, California • La Jolla, California • New Haven, Connecticut + 14 more

Clinical trials in Boston, Massachusetts

Filter and sort this location

Institutions in Boston

Live official records

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

Bionic Pancreas in CFRD

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Health Opportunities and Promoters of Equitable Screening for Lung Cancer

Caries Detection With Two Different Caries Detecting Devices

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment